Chia-Lung Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chia-Lung Tsai has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Neu Tsai
Graduate Institute of Clinical Medical Sciences, College of Medicine Chang Gung University Taoyuan 33302 Taiwan
6 shared publications - Yun-Shien Lee
Department of Biotechnology Ming Chuan University Taoyuan 33348 Taiwan
4 shared publications - Ming-Chin Yu
College of Medicine, Chang Gung University, Taoyuan, Taiwan
3 shared publications - Hong-Yuan Huang
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, 5, Fu-Shin Street, Taoyuan 33301, Taiwan
2 shared publications - Hsien-Ming Wu
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, School of Medicine, Chang Gung University, Taoyuan 333, Taiwan
2 shared publications - Hsin-Shih Wang
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, School of Medicine, Chang Gung University, Taoyuan 333, Taiwan
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9644
RETRACTED: Wu et al. EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility Through Twist and N-Cadherin Signaling. Int. J. Mol. Sci. 2023, 24, 15271
The journal retracts the article titled “EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling”
- 28 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9644
Open AccessRETRACTED: Wu et al. EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility Through Twist and N-Cadherin Signaling. Int. J. Mol. Sci. 2023, 24, 15271
The journal retracts the article titled “EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling”
- 28 April 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (2) , 434-443
Association of GJB2 P.V37I With Sudden Sensorineural Hearing Loss and Endoplasmic Reticulum Stress
Objective: This study aimed to investigate the association between the heterozygous GJB2 p.V37I variant and susceptibility to sudden sensorineural hearing loss (SSNHL), and to explore its potential involvement in endoplasmic reticulum (ER) stress. Study Design: Genetic association study with in vitro functional validation. Setting: Tertiary academic medical center. Methods: We screened 145 SSNHL patients for 25 variants in GJB2, SLC26A4, OTOF, and 12S rRNA using the SNaPshot® Multiplex Assay. GJB2 p.V37I frequency was compared with the Taiwan Biobank, and associations with hearing severity and recurrence were analyzed. Functional studies in HEI‐OC1 cells transfected with wild‐type or p.V37I GJB2 assessed ER stress (GRP78, CHOP) under tunicamycin by Western blot and immunofluorescence. Results: The GJB2 p.V37I variant was identified in 39/145 SSNHL patients (26.9%) and showed significant allele enrichment compared with the general Taiwanese population (8.6%; enrichment OR = 1.92; P < .001), suggesting a genetic susceptibility contribution. The variant was associated with a higher prevalence of moderate (OR, 1.94; P = .019) and severe (OR, 1.90; P = .013) SSNHL, as well as recurrent episodes (OR, 3.77; P = .008). In vitro , p.V37I‐expressing HEI‐OC1 cells, a mouse cochlear hair cell line, showed significantly elevated GRP78 and CHOP expression compared to wild‐type under tunicamycin induced ER stress, as confirmed by both immunoblotting and immunofluorescence microscopy. Conclusion: Our findings indicate that the heterozygous GJB2 p.V37I variant is associated with increased susceptibility and recurrence of SSNHL, potentially through ER stress–related mechanisms, supporting genetic screening and further mechanistic studies.
- 28 April 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (2) , 434-443
Association of GJB2 P.V37I With Sudden Sensorineural Hearing Loss and Endoplasmic Reticulum Stress
Objective: This study aimed to investigate the association between the heterozygous GJB2 p.V37I variant and susceptibility to sudden sensorineural hearing loss (SSNHL), and to explore its potential involvement in endoplasmic reticulum (ER) stress. Study Design: Genetic association study with in vitro functional validation. Setting: Tertiary academic medical center. Methods: We screened 145 SSNHL patients for 25 variants in GJB2, SLC26A4, OTOF, and 12S rRNA using the SNaPshot® Multiplex Assay. GJB2 p.V37I frequency was compared with the Taiwan Biobank, and associations with hearing severity and recurrence were analyzed. Functional studies in HEI‐OC1 cells transfected with wild‐type or p.V37I GJB2 assessed ER stress (GRP78, CHOP) under tunicamycin by Western blot and immunofluorescence. Results: The GJB2 p.V37I variant was identified in 39/145 SSNHL patients (26.9%) and showed significant allele enrichment compared with the general Taiwanese population (8.6%; enrichment OR = 1.92; P < .001), suggesting a genetic susceptibility contribution. The variant was associated with a higher prevalence of moderate (OR, 1.94; P = .019) and severe (OR, 1.90; P = .013) SSNHL, as well as recurrent episodes (OR, 3.77; P = .008). In vitro , p.V37I‐expressing HEI‐OC1 cells, a mouse cochlear hair cell line, showed significantly elevated GRP78 and CHOP expression compared to wild‐type under tunicamycin induced ER stress, as confirmed by both immunoblotting and immunofluorescence microscopy. Conclusion: Our findings indicate that the heterozygous GJB2 p.V37I variant is associated with increased susceptibility and recurrence of SSNHL, potentially through ER stress–related mechanisms, supporting genetic screening and further mechanistic studies.
- Open Access
- 25 April 2026
- Published by Elsevier in SSRN Electronic Journal
Application of a High-Sensitivity Copper Phthalocyanine/Gold Electrochemical Biosensor for Label-Free Biomarker Detection in Ovarian Cancer
Ovarian cancer is frequently diagnosed at an advanced stage due to nonspecific early symptoms and the lack of effective screening tools, resulting in poor clinical outcomes. Herein, we report a simple, rapid, and highly stable electrochemical sensing platform designed for the parallel detection of three ovarian cancer biomarkers. A key advantage of this system is that it enables direct antibody immobilization on copper phthalocyanine-modified gold electrode (Au/CuPc) surface, completely avoiding the need for cross-linking agents or complex activation steps. Comprehensive XPS and Raman spectroscopic analyses reveal that this binding is driven by a "His-tag-like" coordination interaction between the central Cu(II) ion of the CuPc and the imine nitrogen atoms of the antibody's histidine residues. Leveraging this robust mechanism, anti-p53, anti-STIP1, and anti-CA125 were successfully immobilized, facilitating the subsequent detection of their respective antigens via cyclic voltammetry (CV) and differential pulse voltammetry (DPV). The platform exhibited excellent analytical performance, achieving broad linear detection ranges and high sensitivities: 100.0 fg/mL to 1 ng/mL and 22.9 μA/log(pg/mL)·cm² for p53; 12.1 pg/mL to 1.21 μg/mL and 24.09 μA/log(pg/mL)·cm² for STIP1; and 4.4 to 200.0 U/mL and 56.7 μA/log(U/mL)·cm² for CA125. Because the detection ranges for all three target antigens fully encompass established clinical cut-off levels, this electrochemical platform demonstrates strong translational potential as a practical and reliable tool for ovarian cancer detection.
- 25 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessApplication of a High-Sensitivity Copper Phthalocyanine/Gold Electrochemical Biosensor for Label-Free Biomarker Detection in Ovarian Cancer
Ovarian cancer is frequently diagnosed at an advanced stage due to nonspecific early symptoms and the lack of effective screening tools, resulting in poor clinical outcomes. Herein, we report a simple, rapid, and highly stable electrochemical sensing platform designed for the parallel detection of three ovarian cancer biomarkers. A key advantage of this system is that it enables direct antibody immobilization on copper phthalocyanine-modified gold electrode (Au/CuPc) surface, completely avoiding the need for cross-linking agents or complex activation steps. Comprehensive XPS and Raman spectroscopic analyses reveal that this binding is driven by a "His-tag-like" coordination interaction between the central Cu(II) ion of the CuPc and the imine nitrogen atoms of the antibody's histidine residues. Leveraging this robust mechanism, anti-p53, anti-STIP1, and anti-CA125 were successfully immobilized, facilitating the subsequent detection of their respective antigens via cyclic voltammetry (CV) and differential pulse voltammetry (DPV). The platform exhibited excellent analytical performance, achieving broad linear detection ranges and high sensitivities: 100.0 fg/mL to 1 ng/mL and 22.9 μA/log(pg/mL)·cm² for p53; 12.1 pg/mL to 1.21 μg/mL and 24.09 μA/log(pg/mL)·cm² for STIP1; and 4.4 to 200.0 U/mL and 56.7 μA/log(U/mL)·cm² for CA125. Because the detection ranges for all three target antigens fully encompass established clinical cut-off levels, this electrochemical platform demonstrates strong translational potential as a practical and reliable tool for ovarian cancer detection.
- Open Access
- 3 January 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance
Hepatocellular carcinoma (HCC) is a major global health burden. Despite recent advances in immunotherapy, tyrosine kinase inhibitors (TKIs) treatment or combined therapies, therapeutic resistance and disease progression remain significant challenges. SOX4, a transcription factor frequently overexpressed in HCC and other cancers, has been linked to drug resistance and poor prognosis; however, the underlying molecular mechanisms remain unexplored. In this study, we identify STAT6 as a novel transcriptional target and interacting partner of SOX4 in HCC cells. Genetic ablation or knockdown of SOX4 induced hypermethylation of the STAT6 promoter, suppressing its expression, while treatment with the DNA methyltransferase inhibitor 5-Aza-2’-deoxycytidine restored STAT6 levels, indicating an epigenetic mechanism of regulation. In addition, SOX4 is physically associated with STAT6, as confirmed by co-immunoprecipitation and immunofluorescence. SOX4 depletion impaired interleukin-4 (IL-4)-induced phosphorylation of STAT6 at tyrosine residue 641 (Y641), implicating SOX4 in IL-4-mediated STAT6 activation. Chromatin immunoprecipitation (ChIP) assays demonstrated that SOX4 and STAT6 co-occupy the promoter of MTHFD2 , a key enzyme in folate metabolism, regulating NADH/NADPH production and nucleotide biosynthesis. Knockdown of SOX4 or STAT6, or mutation of their binding sites within the MTHFD2 promoter, reduced MTHFD2 expression, NADPH levels, and nucleotide synthesis. Transcriptomic analyses from TCGA-LIHC and our independent cohort revealed a strong positive correlation between SOX4, STAT6, and MTHFD2, with MTHFD2 overexpression linked to poor overall survival. Clinically, elevated SOX4/STAT6/MTHFD2 axis activity was associated with resistance to immunotherapy or TKIs, either in our enrolled cohort or transcriptome data obtained from GSE109211. Metabolomic profiling further revealed increased NADPH and nucleotide biosynthesis in tumors with high SOX4/STAT6/MTHFD2 expression. Targeting STAT6 or MTHFD2 suppressed tumor growth in TKIs-resistant patient-derived xenograft models. Collectively, our findings identify the SOX4–STAT6–MTHFD2 axis as a critical driver of HCC progression and therapeutic resistance, offering a promising target for intervention in refractory HCC.
- 3 January 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessSOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance
Hepatocellular carcinoma (HCC) is a major global health burden. Despite recent advances in immunotherapy, tyrosine kinase inhibitors (TKIs) treatment or combined therapies, therapeutic resistance and disease progression remain significant challenges. SOX4, a transcription factor frequently overexpressed in HCC and other cancers, has been linked to drug resistance and poor prognosis; however, the underlying molecular mechanisms remain unexplored. In this study, we identify STAT6 as a novel transcriptional target and interacting partner of SOX4 in HCC cells. Genetic ablation or knockdown of SOX4 induced hypermethylation of the STAT6 promoter, suppressing its expression, while treatment with the DNA methyltransferase inhibitor 5-Aza-2’-deoxycytidine restored STAT6 levels, indicating an epigenetic mechanism of regulation. In addition, SOX4 is physically associated with STAT6, as confirmed by co-immunoprecipitation and immunofluorescence. SOX4 depletion impaired interleukin-4 (IL-4)-induced phosphorylation of STAT6 at tyrosine residue 641 (Y641), implicating SOX4 in IL-4-mediated STAT6 activation. Chromatin immunoprecipitation (ChIP) assays demonstrated that SOX4 and STAT6 co-occupy the promoter of MTHFD2 , a key enzyme in folate metabolism, regulating NADH/NADPH production and nucleotide biosynthesis. Knockdown of SOX4 or STAT6, or mutation of their binding sites within the MTHFD2 promoter, reduced MTHFD2 expression, NADPH levels, and nucleotide synthesis. Transcriptomic analyses from TCGA-LIHC and our independent cohort revealed a strong positive correlation between SOX4, STAT6, and MTHFD2, with MTHFD2 overexpression linked to poor overall survival. Clinically, elevated SOX4/STAT6/MTHFD2 axis activity was associated with resistance to immunotherapy or TKIs, either in our enrolled cohort or transcriptome data obtained from GSE109211. Metabolomic profiling further revealed increased NADPH and nucleotide biosynthesis in tumors with high SOX4/STAT6/MTHFD2 expression. Targeting STAT6 or MTHFD2 suppressed tumor growth in TKIs-resistant patient-derived xenograft models. Collectively, our findings identify the SOX4–STAT6–MTHFD2 axis as a critical driver of HCC progression and therapeutic resistance, offering a promising target for intervention in refractory HCC.
- Open Access
- 28 October 2025
- Published by Elsevier in Translational Oncology
- Vol. 63, 102573
Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer
- 28 October 2025
- Published by Elsevier in Translational Oncology
- Vol. 63, 102573
Open AccessApplication of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer
- 25 August 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (11) , 1218-1232
NRF2-SOX4 complex regulates PSPH in hepatocellular carcinoma and modulates M2 macrophage differentiation
Hepatocellular carcinoma (HCC) progression is tightly linked to metabolic reprogramming and immune evasion. However, the transcriptional networks driving these processes remain misunderstood. Here, we identified a novel regulatory axis wherein the transcription factor SOX4 formed a stress-responsive complex with NRF2, as confirmed by co-immunoprecipitation and proximity ligation assay. This process was orchestrated via p62-mediated disruption of the KEAP1–SOX4 complex. The SOX4–NRF2 complex directly activated Phosphoserine Phosphatase (PSPH) transcription—as revealed by luciferase reporter and chromatin immunoprecipitation—enhancing serine biosynthesis and downstream metabolites critical for oxidative phosphorylation (OXPHOS) and redox balance. Inhibition of SOX4 or NRF2 impaired PSPH expression, exacerbated oxidative damage—marked by elevated 4-hydroxynonenal—and increased sensitivity to sorafenib treatment in HCC cells. Furthermore, PSPH-driven metabolites, particularly serine, fostered M2-like macrophage polarization, thereby potentially contributing to the promotion of an immunosuppressive tumor microenvironment. Analysis of HCC specimens from TCGA and clinical cohorts confirmed that high SOX4/NRF2/PSPH expression was correlated with increasing M2 macrophage infiltration and poor patient prognosis. Our findings revealed a previously unrecognized SOX4–NRF2–PSPH regulatory loop that coupled cancer metabolism with immune modulation. Targeting this axis may offer a promising therapeutic avenue to simultaneously disrupt metabolic support and immune evasion in HCC.
- 25 August 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (11) , 1218-1232
NRF2-SOX4 complex regulates PSPH in hepatocellular carcinoma and modulates M2 macrophage differentiation
Hepatocellular carcinoma (HCC) progression is tightly linked to metabolic reprogramming and immune evasion. However, the transcriptional networks driving these processes remain misunderstood. Here, we identified a novel regulatory axis wherein the transcription factor SOX4 formed a stress-responsive complex with NRF2, as confirmed by co-immunoprecipitation and proximity ligation assay. This process was orchestrated via p62-mediated disruption of the KEAP1–SOX4 complex. The SOX4–NRF2 complex directly activated Phosphoserine Phosphatase (PSPH) transcription—as revealed by luciferase reporter and chromatin immunoprecipitation—enhancing serine biosynthesis and downstream metabolites critical for oxidative phosphorylation (OXPHOS) and redox balance. Inhibition of SOX4 or NRF2 impaired PSPH expression, exacerbated oxidative damage—marked by elevated 4-hydroxynonenal—and increased sensitivity to sorafenib treatment in HCC cells. Furthermore, PSPH-driven metabolites, particularly serine, fostered M2-like macrophage polarization, thereby potentially contributing to the promotion of an immunosuppressive tumor microenvironment. Analysis of HCC specimens from TCGA and clinical cohorts confirmed that high SOX4/NRF2/PSPH expression was correlated with increasing M2 macrophage infiltration and poor patient prognosis. Our findings revealed a previously unrecognized SOX4–NRF2–PSPH regulatory loop that coupled cancer metabolism with immune modulation. Targeting this axis may offer a promising therapeutic avenue to simultaneously disrupt metabolic support and immune evasion in HCC.
- Open Access
- 17 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15271
RETRACTED: EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling
Crucial roles in embryo implantation and placentation in humans include the invasion of the maternal decidua by extravillous trophoblasts and the motile behavior of decidual endometrial stromal cells. The effects of the epidermal growth factor (EGF) and GnRH-II in the endometrium take part in early pregnancy. In the present study, we demonstrated the coaction of EGF- and GnRH-II-promoted motility of human decidual endometrial stromal cells, indicating the possible roles of EGF and GnRH-II in embryo implantation and early pregnancy. After obtaining informed consent, we obtained human decidual endometrial stromal cells from decidual tissues from normal pregnancies at 6 to 12 weeks of gestation in healthy women undergoing suction dilation and curettage. Cell motility was evaluated with invasion and migration assays. The mechanisms of EGF and GnRH-II were performed using real-time PCR and immunoblot analysis. The results showed that human decidual tissue and stromal cells expressed the EGF and GnRH-I receptors. GnRH-II-mediated cell motility was enhanced by EGF and was suppressed by the knockdown of the endogenous GnRH-I receptor and EGF receptor with siRNA, revealing that GnRH-II promoted the cell motility of human decidual endometrial stromal cells through the GnRH-I receptor and the activation of Twist and N-cadherin signaling. This new concept regarding the coaction of EGF- and GnRH-promoted cell motility suggests that EGF and GnRH-II potentially affect embryo implantation and the decidual programming of human pregnancy.
- 17 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15271
Open AccessRETRACTED: EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling
Crucial roles in embryo implantation and placentation in humans include the invasion of the maternal decidua by extravillous trophoblasts and the motile behavior of decidual endometrial stromal cells. The effects of the epidermal growth factor (EGF) and GnRH-II in the endometrium take part in early pregnancy. In the present study, we demonstrated the coaction of EGF- and GnRH-II-promoted motility of human decidual endometrial stromal cells, indicating the possible roles of EGF and GnRH-II in embryo implantation and early pregnancy. After obtaining informed consent, we obtained human decidual endometrial stromal cells from decidual tissues from normal pregnancies at 6 to 12 weeks of gestation in healthy women undergoing suction dilation and curettage. Cell motility was evaluated with invasion and migration assays. The mechanisms of EGF and GnRH-II were performed using real-time PCR and immunoblot analysis. The results showed that human decidual tissue and stromal cells expressed the EGF and GnRH-I receptors. GnRH-II-mediated cell motility was enhanced by EGF and was suppressed by the knockdown of the endogenous GnRH-I receptor and EGF receptor with siRNA, revealing that GnRH-II promoted the cell motility of human decidual endometrial stromal cells through the GnRH-I receptor and the activation of Twist and N-cadherin signaling. This new concept regarding the coaction of EGF- and GnRH-promoted cell motility suggests that EGF and GnRH-II potentially affect embryo implantation and the decidual programming of human pregnancy.
- Open Access
- 26 November 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (12) , 1898
Glucose Activates Lysine-Specific Demethylase 1 through the KEAP1/p62 Pathway
Endometrial cancer incidence increases annually. Several risk factors, including high glucose intake, are associated with endometrial cancer. We investigated whether glucose affects lysine-specific demethylase 1 (LSD1) expression and the responsible molecular mechanisms. A high concentration of glucose stimulated p62 phosphorylation and increased LSD1 protein expression. Knockdown of p62 or treatment with mammalian target of rapamycin (mTOR), transforming growth factor-β activated kinase 1 (TAK1), casein kinase 1 (CK1), and protein kinase C (PKC) inhibitors abrogated glucose-regulated LSD1 expression. Unphosphorylated p62 and LSD1 formed a complex with Kelch-like ECH-associated protein 1 (KEAP1) and were degraded by the KEAP1-dependent proteasome. Phosphorylated p62 increased LSD1 protein expression by escaping the KEAP1 proteasome complex. LSD1 and KEAP1 interaction was enhanced in the presence of the nuclear factor erythroid 2-related factor 2 (NRF2) protein. LSD1 also participated in antioxidant gene regulation with NRF2. In diabetic mice, increasing LSD1and phospho-p62 expression was observed in uterine epithelial cells. Our results indicate that glucose induces p62 phosphorylation through mTOR, TAK1, CK1, and PKC kinases. Subsequently, phospho-p62 competitively interacts with KEAP1 and releases NRF2–LSD1 from the KEAP1 proteasome complex. Our findings may have public health implications for the prevention of endometrial cancer.
- 26 November 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (12) , 1898
Open AccessGlucose Activates Lysine-Specific Demethylase 1 through the KEAP1/p62 Pathway
Endometrial cancer incidence increases annually. Several risk factors, including high glucose intake, are associated with endometrial cancer. We investigated whether glucose affects lysine-specific demethylase 1 (LSD1) expression and the responsible molecular mechanisms. A high concentration of glucose stimulated p62 phosphorylation and increased LSD1 protein expression. Knockdown of p62 or treatment with mammalian target of rapamycin (mTOR), transforming growth factor-β activated kinase 1 (TAK1), casein kinase 1 (CK1), and protein kinase C (PKC) inhibitors abrogated glucose-regulated LSD1 expression. Unphosphorylated p62 and LSD1 formed a complex with Kelch-like ECH-associated protein 1 (KEAP1) and were degraded by the KEAP1-dependent proteasome. Phosphorylated p62 increased LSD1 protein expression by escaping the KEAP1 proteasome complex. LSD1 and KEAP1 interaction was enhanced in the presence of the nuclear factor erythroid 2-related factor 2 (NRF2) protein. LSD1 also participated in antioxidant gene regulation with NRF2. In diabetic mice, increasing LSD1and phospho-p62 expression was observed in uterine epithelial cells. Our results indicate that glucose induces p62 phosphorylation through mTOR, TAK1, CK1, and PKC kinases. Subsequently, phospho-p62 competitively interacts with KEAP1 and releases NRF2–LSD1 from the KEAP1 proteasome complex. Our findings may have public health implications for the prevention of endometrial cancer.
- 13 May 2020
- Published by Springer Nature in Oncogene
- Vol. 39 (24) , 4695-4710
SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo
The overexpression of SOX4 in various kinds of cancer cells was associated with poor prognosis for patients. The role of SOX4 in angiogenesis and tumor microenvironment modulation was recently documented in breast cancer but remains unclear in hepatocellular carcinoma (HCC). In our study, the clinical relevance of SOX4 overexpression in HCC and its role in the tumor microenvironment were investigated. The overexpression of SOX4 (SOX4high) in tumor lesions was associated with higher microvessel density (P = 0.012), tumor thrombosis formation (P = 0.012), distant metastasis (P < 0.001), and an independent prognostic factor for disease-free survival in HCC patients (P = 0.048). Endogenous SOX4 knockout in Hep3B cells by the CRISPR/cas9 system reduced the expression of CXCL12, which, in turn, attenuated chemotaxis in human umbilical vein endothelial cells, tube formation in vitro, reduced tumor growth, reticular fiber production, and angiogenesis in vivo in a xenograft mouse model. Treatment with an antagonist targeting CXCR4 (AMD3100), a receptor of CXCL12, inhibited chemotaxis and tube formation in endothelial cells in vitro. The CXCL12 promoter was activated by ectopic expression of a Flag-tagged SOX4 plasmid, endogenous SOX4 knockdown abolished promoter activity of CXCL12 as shown by luciferase assays, and an association with the CXCL12 promoter was identified via chromatin immunoprecipitation in HCC cells. In conclusion, SOX4 modulates the CXCL12 promoter in HCC cells. The secretory CXCL12, in turn, modulates CXCR4 in endothelial cells, reticular fibers to regulate the tumor microenvironment and modulate neovascularization, which might contribute to the distant metastasis of tumors.
- 13 May 2020
- Published by Springer Nature in Oncogene
- Vol. 39 (24) , 4695-4710
SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo
The overexpression of SOX4 in various kinds of cancer cells was associated with poor prognosis for patients. The role of SOX4 in angiogenesis and tumor microenvironment modulation was recently documented in breast cancer but remains unclear in hepatocellular carcinoma (HCC). In our study, the clinical relevance of SOX4 overexpression in HCC and its role in the tumor microenvironment were investigated. The overexpression of SOX4 (SOX4high) in tumor lesions was associated with higher microvessel density (P = 0.012), tumor thrombosis formation (P = 0.012), distant metastasis (P < 0.001), and an independent prognostic factor for disease-free survival in HCC patients (P = 0.048). Endogenous SOX4 knockout in Hep3B cells by the CRISPR/cas9 system reduced the expression of CXCL12, which, in turn, attenuated chemotaxis in human umbilical vein endothelial cells, tube formation in vitro, reduced tumor growth, reticular fiber production, and angiogenesis in vivo in a xenograft mouse model. Treatment with an antagonist targeting CXCR4 (AMD3100), a receptor of CXCL12, inhibited chemotaxis and tube formation in endothelial cells in vitro. The CXCL12 promoter was activated by ectopic expression of a Flag-tagged SOX4 plasmid, endogenous SOX4 knockdown abolished promoter activity of CXCL12 as shown by luciferase assays, and an association with the CXCL12 promoter was identified via chromatin immunoprecipitation in HCC cells. In conclusion, SOX4 modulates the CXCL12 promoter in HCC cells. The secretory CXCL12, in turn, modulates CXCR4 in endothelial cells, reticular fibers to regulate the tumor microenvironment and modulate neovascularization, which might contribute to the distant metastasis of tumors.